Combination treatment before surgery for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that is confirmed by a biopsy.
- The tumor should be considered borderline resectable, meaning it's close to blood vessels and surgery is not immediately possible.
- A special test on your biopsy must show a substance called Claudin 18.2 on the tumor cells.
- You should not have had any previous treatment for this cancer (like surgery, chemo, or radiation).
- You need to be between 18 and 75 years old and able to care for yourself (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial tests a combination of chemotherapy, radiation, and immunotherapy (pembrolizumab) before surgery for pancreatic cancer that can be removed. It aims to see if this triple therapy helps shrink tumors and improve survival.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.